GeoVax Labs, Inc. (GOVX)
Oxford Ledge is still expanding full research coverage of GOVX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
GeoVax develops vaccines and immunotherapies for infectious diseases and cancers, prioritizing an mpox/smallpox vaccine candidate in clinical trials.
SEC filings
- 8-K Delisting / transfer of listing 2026-07-10
- 8-K Shareholder vote results 2026-06-17
- S-1 IPO / securities registration statement 2026-05-26
- 8-K Entry into material agreement; 3.02; Regulation FD disclosure; Financial statements and exhibits 2026-05-19
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-14
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for GOVX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open GOVX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.